发明公开
- 专利标题： PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING STRESS URINARY INCONTINENCE OR MIXED INCONTINENCE, AND METHOD FOR SCREENING COMPOUNDS TO BE INCLUDED IN SAID PHARMACEUTICAL COMPOSITION
- 专利标题（中）： 药物组合物治疗或压力性尿失禁或混合性尿失禁和一种筛选化合物的防治中引入该药物组合物
-
申请号： EP13817263.0申请日： 2013-07-09
-
公开(公告)号： EP2884275A1公开(公告)日： 2015-06-17
- 发明人: WATANABE, Toru , KAWABATA, Keiko , WATANABE, Yuka , YUYAMA, Hironori , MASUDA, Noriyuki , BURGARD, Edward C. , THOR, Karl Bruce
- 申请人： Astellas Pharma Inc.
- 申请人地址： 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 专利权人： Astellas Pharma Inc.
- 当前专利权人： Astellas Pharma Inc.
- 当前专利权人地址： 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 代理机构： Hoffmann Eitle
- 优先权： JP2012154319 20120710
- 国际公布： WO2014010603 20140116
- 主分类号： G01N33/15
- IPC分类号： G01N33/15 ; A61K31/343 ; A61K31/381 ; A61K31/4045 ; A61K45/00 ; A61P7/12 ; A61P43/00 ; C12Q1/02 ; G01N33/50 ; C12N15/09
摘要：
[Problem]
To provide a pharmaceutical composition for treating or preventing urinary incontinence on the basis of a novel mechanism of action, and a method for screening a compound to be comprised in the pharmaceutical composition as an active ingredient.
[Means for Solution]
The present invention relates to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, comprising a compound having a melatonin receptor activation action as an active ingredient. Examples of the active ingredient include melatonin, ramelteon, agomelatine, tasimelteon, TIK-301, and the like. Further, the present invention relates to a method for screening a compound to be comprised in a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence as an active ingredient, consisting of a step of measuring a melatonin receptor activation, a step of measuring the contraction of the isolated urethra, a step of measuring the urethral pressure, and the like.
To provide a pharmaceutical composition for treating or preventing urinary incontinence on the basis of a novel mechanism of action, and a method for screening a compound to be comprised in the pharmaceutical composition as an active ingredient.
[Means for Solution]
The present invention relates to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, comprising a compound having a melatonin receptor activation action as an active ingredient. Examples of the active ingredient include melatonin, ramelteon, agomelatine, tasimelteon, TIK-301, and the like. Further, the present invention relates to a method for screening a compound to be comprised in a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence as an active ingredient, consisting of a step of measuring a melatonin receptor activation, a step of measuring the contraction of the isolated urethra, a step of measuring the urethral pressure, and the like.
信息查询
